Industry: Pharma & Healthcare
Published Date: 2026-01-04
Pages: 79 Pages
Report ld: 5558902
Request Sample
Customized Report
Varicella Vaccine Market Size(US$)

CAGR 2026-2032
7.8%
Market Size,2032
USD 8,708
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
The global Varicella Vaccine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2021-2032.
MARKET SEGMENTATION
CHAPTER OUTLINE
Chapter 1: Report scope, segment-level executive summary (by Type, by Application) and market evolution across the short, mid and long term
Chapter 2: Quantitative analysis of Varicella Vaccine sales and revenue at global, regional, and country levels, highlighting market size and growth potential by region
Chapter 3: Competitive landscape of Varicella Vaccine manufacturers (sales, revenue, pricing, market share, industry rankings, and M&A / expansion plans)
Chapter 4: by Type-based segmentation analysis (sales, revenue, pricing, and growth potential) to identify blue-ocean product segments
Chapter 5: by Application-based segmentation analysis (sales, revenue, pricing, and growth potential) to uncover high-value downstream markets
Chapter 6: Regional breakdown by company, customer, by Type and by Application (sales, revenue, and pricing for each segment)
Chapter 7: Key manufacturer profiles –company overview, Varicella Vaccine product descriptions and specifications, revenue, gross margins, and recent developments
Chapter 8: Industry chain analysis – upstream raw materials, manufacturing links, and downstream application sectors
Chapter 9: Sales channels and distributor analysis – routes to market and key customer interfaces
Chapter 10: Market dynamics – trends, drivers, restraints, risks for manufacturers, and the impact of relevant industry policies
Chapter 11: Key findings, main takeaways, and overall conclusions of the report.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Varicella Vaccine value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Varicella Vaccine Product Scope
1.2 Varicella Vaccine by Type
1.2.1 Global Varicella Vaccine Sales by Type (2021, 2025 & 2032)
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Varicella Vaccine by Application
1.3.1 Global Varicella Vaccine Sales Comparison by Application (2021, 2025 & 2032)
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Global Varicella Vaccine Market Estimates and Forecasts (2021-2032)
1.4.1 Global Varicella Vaccine Market Size (Value) and Growth Rate (2021-2032)
1.4.2 Global Varicella Vaccine Market Size (Volume) and Growth Rate (2021-2032)
1.4.3 Global Varicella Vaccine Price Trends (2021-2032)
1.5 Assumptions and Limitations
2 Market Size and Prospects by Region
2.1 Global Varicella Vaccine Market Size by Region: 2021 VS 2025 VS 2032
2.2 Global Varicella Vaccine Historical Market Scenario by Region (2021-2026)
2.2.1 Global Varicella Vaccine Sales Market Share by Region (2021-2026)
2.2.2 Global Varicella Vaccine Revenue Market Share by Region (2021-2026)
2.3 Global Varicella Vaccine Market Estimates and Forecasts by Region (2027-2032)
2.3.1 Global Varicella Vaccine Sales Estimates and Forecasts by Region (2027-2032)
2.3.2 Global Varicella Vaccine Revenue Forecast by Region (2027-2032)
2.4 Major Regions and Emerging Market Analysis
2.4.1 North America Varicella Vaccine Market Size and Prospects (2021-2032)
2.4.2 Europe Varicella Vaccine Market Size and Prospects (2021-2032)
2.4.3 China Varicella Vaccine Market Size and Prospects (2021-2032)
2.4.4 Japan Varicella Vaccine Market Size and Prospects (2021-2032)
2.4.5 South Korea Varicella Vaccine Market Size and Prospects (2021-2032)
3 Global Market Size by Type
3.1 Global Varicella Vaccine Historical Market Review by Type (2021-2026)
3.1.1 Global Varicella Vaccine Sales by Type (2021-2026)
3.1.2 Global Varicella Vaccine Revenue by Type (2021-2026)
3.1.3 Global Varicella Vaccine Average Price by Type (2021-2026)
3.2 Global Varicella Vaccine Market Estimates and Forecasts by Type (2027-2032)
3.2.1 Global Varicella Vaccine Sales Forecast by Type (2027-2032)
3.2.2 Global Varicella Vaccine Revenue Forecast by Type (2027-2032)
3.2.3 Global Varicella Vaccine Price Forecast by Type (2027-2032)
3.3 Representative Players for Different Types of Varicella Vaccine
4 Global Market Size by Application
4.1 Global Varicella Vaccine Historical Market Review by Application (2021-2026)
4.1.1 Global Varicella Vaccine Sales by Application (2021-2026)
4.1.2 Global Varicella Vaccine Revenue by Application (2021-2026)
4.1.3 Global Varicella Vaccine Average Price by Application (2021-2026)
4.2 Global Varicella Vaccine Market Estimates and Forecasts by Application (2027-2032)
4.2.1 Global Varicella Vaccine Sales Forecast by Application (2027-2032)
4.2.2 Global Varicella Vaccine Revenue Forecast by Application (2027-2032)
4.2.3 Global Varicella Vaccine Price Forecast by Application (2027-2032)
4.3 New Sources of Growth in Varicella Vaccine Applications
5 Competition Landscape by Players
5.1 Global Varicella Vaccine Sales by Player (2021-2026)
5.2 Global Top Varicella Vaccine Players by Revenue (2021-2026)
5.3 Global Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3), based on Varicella Vaccine revenue as of 2025
5.4 Global Varicella Vaccine Average Price by Company (2021-2026)
5.5 Global Key Manufacturers of Varicella Vaccine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Varicella Vaccine, Product Type & Application
5.7 Global Key Manufacturers of Varicella Vaccine, Date of Entry into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Regional Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Varicella Vaccine Sales by Company
6.1.1.1 North America Varicella Vaccine Sales by Company (2021-2026)
6.1.1.2 North America Varicella Vaccine Revenue by Company (2021-2026)
6.1.2 North America Varicella Vaccine Sales Breakdown by Type (2021-2026)
6.1.3 North America Varicella Vaccine Sales Breakdown by Application (2021-2026)
6.1.4 North America Varicella Vaccine Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Varicella Vaccine Sales by Company
6.2.1.1 Europe Varicella Vaccine Sales by Company (2021-2026)
6.2.1.2 Europe Varicella Vaccine Revenue by Company (2021-2026)
6.2.2 Europe Varicella Vaccine Sales Breakdown by Type (2021-2026)
6.2.3 Europe Varicella Vaccine Sales Breakdown by Application (2021-2026)
6.2.4 Europe Varicella Vaccine Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Varicella Vaccine Sales by Company
6.3.1.1 China Varicella Vaccine Sales by Company (2021-2026)
6.3.1.2 China Varicella Vaccine Revenue by Company (2021-2026)
6.3.2 China Varicella Vaccine Sales Breakdown by Type (2021-2026)
6.3.3 China Varicella Vaccine Sales Breakdown by Application (2021-2026)
6.3.4 China Varicella Vaccine Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Varicella Vaccine Sales by Company
6.4.1.1 Japan Varicella Vaccine Sales by Company (2021-2026)
6.4.1.2 Japan Varicella Vaccine Revenue by Company (2021-2026)
6.4.2 Japan Varicella Vaccine Sales Breakdown by Type (2021-2026)
6.4.3 Japan Varicella Vaccine Sales Breakdown by Application (2021-2026)
6.4.4 Japan Varicella Vaccine Major Customers
6.4.5 Japan Market Trends and Opportunities
6.5 South Korea Market: Players, Segments, Downstream and Major Customers
6.5.1 South Korea Varicella Vaccine Sales by Company
6.5.1.1 South Korea Varicella Vaccine Sales by Company (2021-2026)
6.5.1.2 South Korea Varicella Vaccine Revenue by Company (2021-2026)
6.5.2 South Korea Varicella Vaccine Sales Breakdown by Type (2021-2026)
6.5.3 South Korea Varicella Vaccine Sales Breakdown by Application (2021-2026)
6.5.4 South Korea Varicella Vaccine Major Customers
6.5.5 South Korea Market Trends and Opportunities
7 Company Profiles and Key Figures
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Business Overview
7.1.3 Merck Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.1.4 Merck Varicella Vaccine Products Offered
7.1.5 Merck Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Business Overview
7.2.3 GSK Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.2.4 GSK Varicella Vaccine Products Offered
7.2.5 GSK Recent Development
7.3 Shanghai Institute
7.3.1 Shanghai Institute Company Information
7.3.2 Shanghai Institute Business Overview
7.3.3 Shanghai Institute Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.3.4 Shanghai Institute Varicella Vaccine Products Offered
7.3.5 Shanghai Institute Recent Development
7.4 BCHT
7.4.1 BCHT Company Information
7.4.2 BCHT Business Overview
7.4.3 BCHT Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.4.4 BCHT Varicella Vaccine Products Offered
7.4.5 BCHT Recent Development
7.5 Changsheng
7.5.1 Changsheng Company Information
7.5.2 Changsheng Business Overview
7.5.3 Changsheng Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.5.4 Changsheng Varicella Vaccine Products Offered
7.5.5 Changsheng Recent Development
7.6 Keygen
7.6.1 Keygen Company Information
7.6.2 Keygen Business Overview
7.6.3 Keygen Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.6.4 Keygen Varicella Vaccine Products Offered
7.6.5 Keygen Recent Development
7.7 Green Cross
7.7.1 Green Cross Company Information
7.7.2 Green Cross Business Overview
7.7.3 Green Cross Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.7.4 Green Cross Varicella Vaccine Products Offered
7.7.5 Green Cross Recent Development
7.8 Biken
7.8.1 Biken Company Information
7.8.2 Biken Business Overview
7.8.3 Biken Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
7.8.4 Biken Varicella Vaccine Products Offered
7.8.5 Biken Recent Development
8 Varicella Vaccine Manufacturing Cost Analysis
8.1 Varicella Vaccine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Varicella Vaccine
8.4 Varicella Vaccine Industrial Chain Analysis
9 Marketing Channels, Distributors and Customers
9.1 Marketing Channels
9.2 Varicella Vaccine Distributors List
9.3 Varicella Vaccine Customers
10 Varicella Vaccine Market Dynamics
10.1 Varicella Vaccine Industry Trends
10.2 Varicella Vaccine Market Drivers
10.3 Varicella Vaccine Market Challenges
10.4 Varicella Vaccine Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 114
USD 2900.00
(Single User License)
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 149
USD 4900.00
(Single User License)
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 135
USD 5900.00
(Single User License)
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 77
USD 4250.00
(Single User License)
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-17
Pages: 140
USD 5600.00
(Single User License)
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 114
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 149
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 135
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 77
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-17
Pages: 140
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now